Actively Recruiting
Association of Gene Polymorphism With Susceptibility to Type 2 Diabetes Mellitus and Responses to Exenatide in Chinese Patients
Led by The Affiliated Hospital of Xuzhou Medical University · Updated on 2025-09-18
300
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating how genetic differences affect the response to GLP-1 receptor agonists, like exenatide, in people with type 2 diabetes mellitus (T2DM). This study focuses on the impact of various gene polymorphisms linked to T2DM susceptibility on the effectiveness of these diabetes medications. Understanding these genetic influences can help tailor treatment plans for better blood sugar control and weight management. Eligible patients with T2DM who have been treated with GLP-1 receptor agonists through subcutaneous injections at standard doses for six consecutive months are included. Patients are grouped based on their response to treatment, considering blood sugar reduction and weight loss. Blood samples are collected for genotyping before treatment, and patients are categorized into responders or non-responders after six months. Participants attend visits at the start, three months, and six months of treatment, where medical history, physical exams, and routine lab tests are conducted. Researchers measure changes in blood sugar control (HbA1c) and body weight to evaluate treatment effectiveness. They also assess factors influencing treatment response and monitor for any side effects over the six months. This study aims to identify variables that predict drug efficacy to support personalized diabetes care.
CONDITIONS
Brief Title
Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DM
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of type 2 diabetes mellitus
- Body mass index (BMI) between 20 and 35 kg/m2
- HbA1c between 7.0% and 12%
- Age between 25 and 70 years
- Available required data at baseline and 6 months after GLP-1 receptor agonist therapy
You will not qualify if you...
- Serious diseases such as recent heart attack, stroke, trauma, kidney or liver diseases, severe gastrointestinal dysfunction, or history of pancreatitis
- Use of GLP-1 analogues, weight loss drugs, glucocorticoids, or drugs affecting gastrointestinal movement in the past 3 months
- Missing data at baseline, 3 months, or 6 months after GLP-1 receptor agonist therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 6 months
Participants receive subcutaneous injections of a GLP-1 receptor agonist at a standard dose and frequency for 6 consecutive months.
Visits at months 0, 3, and 6 for medical history, physical examinations, and laboratory tests
Trial Site Locations
Total: 1 location
1
China, Jiangsu, Department of Endocrinology
Xuzhou, China, China, 221006
Actively Recruiting
Research Team
T
Tao Wang, Ph.D
X
Xiaoxing Yin, Ph.D
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
PREVENTION
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here